Phase II study of TAK 875 (Takeda) shows improved glycemic control in patients with Type 2 Diabetes

Phase II data for TAK 875, from Takeda, demonstrated that at doses ranging from 6.25 to 200 mg a day, the drug met its primary endpoint of statistically significantly lowering HbA1c (blood glucose) levels over a 12-week period versus placebo in patients with Type 2 Diabetes. This was achieved without significant increase in the incidence of hypoglycemia. The study evaluated five different doses of TAK 875 (6.25 mg, 25 mg, 50 mg, 100 mg, and 200 mg), compared with placebo and glimepiride over 12 weeks. Results demonstrated that all doses showed significantly greater HbA1c reductions at week 12 versus placebo, and was comparable to the HbA1c reductions with glimepiride. Compared to placebo, more than twice as many patients (40.4 percent) treated with 50 mg of TAK 875 achieved HbA1c less than seven percent at week 12. The overall incidence of adverse events was similar for TAK 875 and placebo. The data was published online in The Lancet: "TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a Phase II randomised, double-blind, placebo-controlled trial" Charles F Burant et al The Lancet, Early Online Publication, 27 February 2012 doi:10.1016/S0140-6736(11)61879-5